Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20‐APP transgenic and wild‐type mice
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative pathology characterized by aggregates of amyloid‐β (Aβ) and phosphorylated tau protein, synaptic dysfunction, and spatial memory impairment. The Wnt signaling pathway has several key functions in the adult brain and has been associated with AD, mainly as a neuroprotective factor against Aβ toxicity and tau phosphorylation. However, dysfunction of Wnt/β‐catenin signaling might also play a role in the onset and development of the disease. J20 APP swInd transgenic (Tg) mouse model of AD was treated i.p. with various Wnt signaling inhibitors for 10 weeks during pre‐symptomatic stages. Then, cognitive, biochemical and histochemical analyses were performed. Wnt signaling inhibitors induced severe changes in the hippocampus, including alterations in Wnt pathway components and loss of Wnt signaling function, severe cognitive deficits, increased tau phosphorylation and Aβ 1–42 peptide levels, decreased Aβ42/Aβ40 ratio and Aβ 1–42 concentration in the cerebral spinal fluid, and high levels of soluble Aβ species and synaptotoxic oligomers in the hippocampus, together with changes in the amount and size of senile plaques. More important, we also observed severe alterations in treated wild‐type (WT) mice, including behavioral impairment, tau phosphorylation, increased Aβ 1–42 in the hippocampus, decreased Aβ 1–42 in the cerebral spinal fluid, and hippocampal dysfunction. Wnt inhibition accelerated the development of the pathology in a Tg AD mouse model and contributed to the development of Alzheimer's‐like changes in WT mice. These results indicate that Wnt signaling plays important roles in the structure and function of the adult hippocampus and suggest that inhibition of the Wnt signaling pathway is an important factor in the pathogenesis of AD. image Read the Editorial Highlight for this article on page 356.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“…evaluation of the presence of high-molecular-weight oligomers via a slot-blot assay using the A11 antibody, which binds to a specific oligomeric conformation (Lesne et al. 2006), revealed that AS-treated Tg mice exhibited higher levels of this species compared with the control Tg mice (Fig.”
BackgroundInfluentialRetractedWnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 2×
“the deposition of senile plaque deposits (Mucke et al. 2000) and the”
BackgroundBourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800 · cited 2×
“2012), and promotes the expression of genes involved in LTP and memory (Bourtchuladze et al. 1994; Kasahara et al. 2001).”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 2×
“Alzheimer’s disease (AD), the most common form of dementia, is characterized by a progressive loss of learning and memory concomitant with the presence of senile plaques (SPs) and neurofibrillary tangles (NFTs) in the hippocampus and cerebral cortex (Huang and Mucke 2012).”
BackgroundShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“…produced by the sequential cleavage of amyloid precursor protein (APP) by the b- and c-secretase enzymes (De Strooper et al. 2010), followed by the formation of oligomers (Walsh et al. 2002; Yoshiike et al. 2003; Shankar et al. 2007, 2008), and finally the appearance of SPs (Mucke and Selkoe 2012).”
BackgroundWnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors
Gordon, M. D., & Nusse, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600015200 · Cited by 1,333
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“(2018) 144, 443--465 443 of AD cases increase dramatically as the population ages (Qiu et al. 2009).”
BackgroundThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis
Daneman, R., Agalliu, D., Zhou, L., Kuhnert, F., Kuo, C. J., & Barres, B. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805165106 · Cited by 753
Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis
McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., Marquez, R., & Alessi, D. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600633 · Cited by 594
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532 · cited 2×
“In AD patients, this ratio is drastically altered because Ab1–42 formation is increased, triggering the neurodegenerative process (Pauwels et al. 2011), and increased Ab42/Ab40 ratios correlate with earlyonset FAD (Kumar-Singh et al. 2006) and increased neurotoxicity (Kuperstein et al. 2010).”
BackgroundWnt signaling through Dishevelled, Rac and JNK regulates dendritic development
Rosso, S. B., Sussman, D., Wynshaw-Boris, A., & Salinas, P. C. (2005) · Nature Neuroscience · doi:10.1038/nn1374 · Cited by 485
Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal
Hardy, J. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s317 · Cited by 475 · cited 1×
“According to the amyloid cascade hypothesis, the neurodegenerative process begins with the formation of the amyloid-b (Ab) peptide (Hardy 2006; Barage and Sonawane 2015; Musiek and Holtzman 2015).”
BackgroundPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Post-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437 · cited 1×
“First, we evaluated the T231 and S235 epitopes in the tau protein because these residues have been associated with inhibition of the binding of tau to microtubules and triggering the process of tau aggregation (Sengupta et al. 1998; Gong et al. 2005).”
MethodPalop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G.-Q., Raber, J., Masliah, E., & Mucke, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133381100 · Cited by 402
Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., Kametani, F., Maeda, M., Saido, T. C., Wang, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1575-04.2005 · Cited by 391 · cited 1×
“APP processing generates Ab peptides that differ in length at their carboxy termini (Sato et al. 2003; Qi-Takahara et al. 2005; Kakuda et al. 2006).”
BackgroundGSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Wnt signaling in the nervous system and in Alzheimer's disease
Inestrosa, N. C., & Varela-Nallar, L. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt051 · Cited by 324
Self-citationActivity-dependent synaptic Wnt release regulates hippocampal long term potentiation
Chen, J., Park, C. S., & Tang, S.-J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511920200 · Cited by 298 · cited 1×
“The suppression of Wnt signaling affects long-term potentiation (LTP), a neurophysiological correlate of learning and memory (Chen et al. 2006).”
BackgroundJan, A., Gokce, O., Luthi-Carter, R., & Lashuel, H. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803159200 · Cited by 291
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509695103 · Cited by 239
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223
Liu, C.-C., Tsai, C.-W., Deak, F., Rogers, J., Penuliar, M., Sung, Y. M., Maher, J. N., Fu, Y., Li, X., Xu, H., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.048 · Cited by 222 · cited 1×
“Deletion of the Lrp6 gene in a mouse model of AD also exacerbates amyloid deposition (Liu et al. 2014), suggesting that Wnt signaling dysfunction is a possible mechanism by which FAD mutations lead to the early development and rapid progression of AD (Baki et al. 2004).”
BackgroundVarela-Nallar, L., Alfaro, I. E., Serrano, F. G., Parodi, J., & Inestrosa, N. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010011107 · Cited by 197
Self-citationThe secreted Wnt antagonist Dickkopf-1 is required for amyloid β-mediated synaptic loss
Purro, S. A., Dickins, E. M., & Salinas, P. C. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4562-11.2012 · Cited by 195
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152 · cited 1×
“Another possibility is a reduced efflux from the brain across the BBB, which have been associated with AD (Honjo et al. 2012; Luissint et al. 2012).”
BackgroundFarías, G. G., Vallés, A. S., Colombres, M., Godoy, J. A., Toledo, E. M., Lukas, R. J., Barrantes, F. J., & Inestrosa, N. C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3934-06.2007 · Cited by 108
Self-citationWnt/β-Catenin Signaling in Alzheimer’s Disease
Ferrari, G., Avila, M., Medina, M., Perez-Palma, E., Bustos, B., & Alarcon, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527312666131223113900 · Cited by 95
Neuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.117 · Cited by 83
Mateo, I., Infante, J., Llorca, J., Rodríguez, E., Berciano, J., & Combarros, O. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091044 · Cited by 53 · cited 2×
“Furthermore, a polymorphism in the promoter of GSK-3 that increases its activity is a risk factor for lateonset AD (Mateo et al. 2006), and an allele of low-density lipoprotein receptor-related protein-6 (LRP6) associated with a loss of function of Wnt signaling is a susceptibility gene for…”
BackgroundCavieres, V. A., González, A., Muñoz, V. C., Yefi, C. P., Bustamante, H. A., Barraza, R. R., Tapia-Rojas, C., Otth, C., Barrera, M. J., González, C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136313 · Cited by 43
Self-citation
Cited by
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288
“AD-like pathology in an AD mouse model overexpressed human APP with two FAD mutations [76].”
BackgroundWnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease.
Inestrosa, N., & Tapia-Rojas, C. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238606 · Cited by 137
Self-citationPetrache, A. L., Rajulawalla, A., Shi, A., Wetzel, A., Saito, T., Saido, T. C., Harvey, K., & Ali, A. B. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz016 · Cited by 124
Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease
Folke, J., Pakkenberg, B., & Brudek, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1103-z · Cited by 123
Metadata
- Authors
- Tapia‐Rojas, C., & Inestrosa, N. C.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2018-01-26
- Volume
- 144
- Issue
- 4
- Pages
- 443-465
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2773591307
- Cited by
- 85
- References
- 42
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.